Nevirapine (NVP) is an anti-retroviral drug used for the treatment of HIV infection, that may cause several severe adverse events, including Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). A recent whole genome association study highlighted a strong association with allopurinol-induced SJS/TEN within the HCP5 and PSORS1C1 genes in the Japanese population. Our aim was to verify the contribution of these two genes in the susceptibility to NVP-induced SJS/TEN in a population from Mozambique.

Borgiani, P., Di Fusco, D., Erba, F., Marazzi, M., Mancinelli, S., Novelli, G., et al. (2014). HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons syndrome/toxic epidermal necrolysis susceptibility in a population from Mozambique. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 70(3), 275-278 [10.1007/s00228-013-1622-5].

HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons syndrome/toxic epidermal necrolysis susceptibility in a population from Mozambique

BORGIANI, PAOLA;ERBA, FULVIO;MANCINELLI, SANDRO;NOVELLI, GIUSEPPE;PALOMBI, LEONARDO;CICCACCI, CINZIA
2014-03-01

Abstract

Nevirapine (NVP) is an anti-retroviral drug used for the treatment of HIV infection, that may cause several severe adverse events, including Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). A recent whole genome association study highlighted a strong association with allopurinol-induced SJS/TEN within the HCP5 and PSORS1C1 genes in the Japanese population. Our aim was to verify the contribution of these two genes in the susceptibility to NVP-induced SJS/TEN in a population from Mozambique.
mar-2014
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/03 - GENETICA MEDICA
English
Borgiani, P., Di Fusco, D., Erba, F., Marazzi, M., Mancinelli, S., Novelli, G., et al. (2014). HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons syndrome/toxic epidermal necrolysis susceptibility in a population from Mozambique. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 70(3), 275-278 [10.1007/s00228-013-1622-5].
Borgiani, P; Di Fusco, D; Erba, F; Marazzi, M; Mancinelli, S; Novelli, G; Palombi, L; Ciccacci, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
HCP5 genetic variant (RS3099844) contributes to Nevirapine.pdf

solo utenti autorizzati

Licenza: Non specificato
Dimensione 235.18 kB
Formato Adobe PDF
235.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/85890
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 14
social impact